Frank Jacobsen

Frank Jacobsen

Auto-generated profile, based on publicly available information

Frank Jacobsen

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2017 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
AHA. Hinsch
A. Hinsch
MBMalte Buchholz
Malte Buchholz
SOS. Odinga
S. Odinga
CBC. Borkowski
C. Borkowski
CKC. Koop
C. Koop
Hartmut SchlüterHartmut Schlüter
Hartmut Schlüter

1 December 2021 in Pathology - Research and Practice
Verified
Journal Article
Open access
KJKristina Jansen
Kristina Jansen
NFNagina Farahi
Nagina Farahi
FBFranziska Büscheck
Franziska Büscheck
MLMaximilian Lennartz
Maximilian Lennartz
ALAndreas Luebke
Andreas Luebke
SSStefan Steurer
Stefan Steurer
DOG1 (Discovered on GIST1) is a voltage-gated calcium-activated chloride and bicarbonate channel that is highly expressed in interstitial cells of Cajal and in gastrointestinal stromal tumors (GIST) derived from Cajal cells. To systematically determine in what tumor entities and normal tissue types DOG1 may be further expressed, a tissue microarray (TMA) containing 15,965 samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. DOG1 immunostaining was found in 67 tumor types including GIST (95.7%), esophageal squamous cell carcinoma (31.9%), pancreatic ductal adenocarcinoma (33.6%), adenocarcinoma of the Papilla Vateri (20%), squamous cell carcinoma of the vulva (15.8%) and the oral cavity (15.3%), mucinous ovarian cancer (15.3%), esophageal adenocarcinoma (12.5%), endometrioid endometrial cancer (12.1%), neuroendocrine carcinoma of the colon (11.1%) and diffuse gastric adenocarcinoma (11%). Low level-DOG1 immunostaining was seen in 17 additional tumor entities. DOG1 expression was unrelated to histopathological parameters of tumor aggressiveness and/or patient prognosis in cancers of the breast (n = 1002), urinary bladder (975), ovary (469), endometrium (173), stomach (233), and thyroid gland (512). High DOG1 expression was linked to estrogen receptor expression in breast cancer (p < 0.0001) and absence of HPV infection in squamous cell carcinomas (p = 0.0008). In conclusion, our data identify several tumor entities that can show DOG1 expression levels at similar levels as in GIST. Although DOG1 is tightly linked to a diagnosis of GIST in spindle cell tumors, the differential diagnosis is much broader in DOG1 positive epithelioid neoplasms.

28 March 2023 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
EBElena Bady
Elena Bady
KMKatharina Moeller
Katharina Moeller
TMTim Mandelkow
Tim Mandelkow
JRJonas B. Raedler
Jonas B. Raedler
CYCheng Yang
Cheng Yang
NBNiclas Christian Blessin
Niclas Christian Blessin
Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance. Implications: The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.

25 October 2012 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
FJFrank Jacobsen
Frank Jacobsen
SASharad Nouraie Ashtiani
Sharad Nouraie Ashtiani
PTPierre Tennstedt
Pierre Tennstedt
HHHans Heinzer
Hans Heinzer
RSRonald Simon
Ronald Simon
UMUwe Michl
Uwe Michl
C-MET is considered a possible therapeutic target in numerous tumor types and is also a candidate regulator of response to anti-HER2 and anti-epidermal growth factor receptor (EGFR) therapy. The aim of this study was to determine the prevalence and clinical significance of c-MET expression in hormone-naïve prostate cancers. A pre-existing prostate tissue microarray (TMA) containing samples of 4,177 patients treated by radical prostatectomy was used. A total of 3,378 different prostate cancers were successfully analyzed for c-MET expression by immunohistochemistry and follow-up data were available for 4,104 patients. Membranous c-MET immunostaining was performed for 2,655 (78.6%) tumors. High c-MET protein expression was significantly associated with a high Gleason grade (P=0.0018). However, c-MET was not a prognostic marker for biochemical recurrence. c-MET levels were also not associated with other parameters, including tumor stage, nodal stage and surgical margin status. The c-MET protein is often overexpressed in prostate cancer, but has no prognostic relevance. However, the frequent presence of high levels of membranous c-MET protein in prostate cancer cells makes c-MET an attractive target for imaging and treatment.

1 June 2023
Verified
Other
Open access
EBElena Bady
Elena Bady
KMKatharina Möller
Katharina Möller
TMTim Mandelkow
Tim Mandelkow
JRJonas B. Raedler
Jonas B. Raedler
CYCheng Yang
Cheng Yang
NBNiclas Christian Blessin
Niclas Christian Blessin
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.

27 November 2025
Verified
Other
Open access
EBElena Bady
Elena Bady
KMKatharina Möller
Katharina Möller
TMTim Mandelkow
Tim Mandelkow
JRJonas B. Raedler
Jonas B. Raedler
CYCheng Yang
Cheng Yang
NBNiclas Christian Blessin
Niclas Christian Blessin
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.